(Q39807616)

English

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

scientific article

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Munir Pirmohamed

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Athina Giannoudis

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Heather G Jørgensen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Joanne C Mountford

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

A Davies

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

N E Jordanides

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

S Hatziieremia

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

R J Harris

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

R E Clark

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

27 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1999-2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19710702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2009.166

0 references

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Punish the parent not the progeny.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Changing picture of cellular drug resistance in human leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

21 January 2018

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39807616&oldid=2090649128"